Molecular pathogenesis of acute promyelocytic leukaemia and APL variants

Best Practice and Research: Clinical Haematology

Volumn 16, Issue 3, 2003, Pages 387-408

  Sirulnik, Andres ^a   Melnick, Ari ^b   Zelent, Arthur ^c   Licht, Jonathan D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Acute promyelocytic leukaemia; PLZF; PML; Retinoic acid receptor; Transcriptional repression

Indexed keywords

ANTINEOPLASTIC AGENT; AZACITIDINE; CELL CYCLE PROTEIN; CELL NUCLEUS RECEPTOR; HISTONE DEACETYLASE INHIBITOR; HYBRID PROTEIN; NUCLEAR PROTEIN; PHOSPHOPROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; STAT5B PROTEIN; ZINC FINGER PROTEIN; NUCLEOPHOSMIN; PROTEIN NUCLEAR MITOTIC APPARATUS; UNCLASSIFIED DRUG;

CELL DIFFERENTIATION; CELL GROWTH; CELL MATURATION; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 17; DRUG SENSITIVITY; FUSION GENE; GENE EXPRESSION REGULATION; GENE REARRANGEMENT; GENE TRANSLOCATION; HEMATOPOIETIC CELL; HUMAN; MOLECULAR GENETICS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REVIEW; CHROMOSOME TRANSLOCATION; DRUG EFFECT; DRUG MECHANISM; GENE FUSION; KARYOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 0041327719     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6926(03)00062-8     Document Type: Review

References (176)

1. Mandelli F, Avvisati G & Lo Coco F. Advances in the understanding and management of acute promyelocytic leukemia. Reviews in Clinical & Experimental Hematology 2002; 6: 60-71; discussion 86-87.
2. Rowley J, Golumb H & Dougherty C. 15/17 translocation a consistent chromosomal change in acute promyelocytic leukaemia. Lancet 1977; i: 549-550.
3. de Thé H, Chomienne C, Lanotte M et al. The t(15;17) translocation of acute promyelocytic leukemia fuses the retinoic acid receptor α gene to a novel transcribed locus. Nature 1990; 347: 1990.
4. Kakizuka A, Miller WJ, Umesono K et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 1991; 66: 663-674.
5. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB Journal 1996; 10: 940-954.
6. Mangelsdorf DJ, Thummel C, Beato M et al. The nuclear receptor superfamily: the second decade. Cell 1995; 83: 835-839.
7. Mangelsdorf DJ, Borgmeyer U, Heyman RA et al. Characterization of three RXR genes that mediate the action of 9-cis retinoic acid. Genes & Development 1992; 6: 329-344.
8. Glass CK & Rosenfeld MG. The coregulator exchange in transcriptional functions of nuclear receptors. Genes & Development 2000; 14: 121-141.
9. Renaud JP, Rochel N, Ruff M et al. Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid. Nature 1995; 378: 681-689.
10. Bourguet W, Ruff M, Chambon P et al. Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-alpha. Nature 1995; 375: 377-382.
11. Collins SJ. The role of retinoids and retinoic acid receptors in normal hematopoiesis. Leukemia 2002; 16: 1896-1905.
12. Melnick A & Licht JD. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999; 93: 3167-3215.
13. Lawson ND & Berliner N. Neutrophil maturation and the role of retinoic acid. Experimental Hematology 1999; 27: 1355-1367.
14. Kastner P & Chan S. Function of RARalpha during the maturation of neutrophils. Oncogene 2001; 20: 7178-7185.
15. Kuwata T, Wang IM, Tamura T et al. Vitamin A deficiency in mice causes a systemic expansion of myeloid cells. Blood 2000; 95: 3349-3356.
16. Kastner P, Lawrence HJ, Waltzinger C et al. Positive and negative regulation of granulopoiesis by endogenous RARalpha. Blood 2001; 97: 1314-1320.
17. Tsai S & Collins SJ. A dominant negative retinoic acid receptor blocks neutrophil differentiation at the promyelocyte stage. Proceedings of the National Academy of Sciences of the USA 1993; 90: 7153-7157.
18. Li E, Sucov HM, Lee KF et al. Normal development and growth of mice carrying a targeted disruption of the alpha 1 retinoic acid receptor gene. Proceedings of the National Academy of Sciences of the USA 1993; 90: 1590-1594.
19. Labrecque J, Allan D, Chambon P et al. Impaired granulocytic differentiation in vitro in hematopoietic cells lacking retinoic acid receptors alpha 1 and gamma. Blood 1998; 92: 607-615.
20. Lohnes D, Kastner P, Dierich A et al. Function of retinoic acid receptor gamma in the mouse. Cell 1993; 73: 643-658.
21. Lohnes D, Mark M, Mendelsohn C et al. Function of the retinoic acid receptors (RARs) during development. 1. Craniofacial and skeletal abnormalities in RAR double mutants. Development. 1994; 120: 2723-2748.
22. Alcalay M, Zangrilli D, Pandolfi PP et al. Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor alpha locus. Proceedings of the National Academy of Sciences of the USA 1991; 88: 1977-1981.
23. Chen Z, Brand NJ, Chen A et al. Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. EMBO Journal 1993; 12: 1161-1167.
24. Corey SJ, Locker J, Oliveri DR et al. A non-classical translocation involving 17q12 (retinoic acid receptor alpha) in acute promyelocytic leukemia (APML) with atypical features. Leukemia 1994; 8: 1350-1353.
25. Redner RL, Rush EA, Faas S et al. The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood 1996; 87: 882-886.
26. Wells RA, Hummel JL, De Koven A et al. A new variant translocation in acute promyelocytic leukemia: molecular characterization and clinical correlation. Leukemia 1996; 10: 735-740.
27. Wells RA, Catzavelos C & Kamel-Reid S. Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia. Nature Genetics 1997; 17: 109-113.
28. Arnould C, Philippe C, Bourdon V et al. The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia. Human Molecular Genetics 1999; 8: 1741-1749.
29. Grimwade D, Biondi A, Mozziconacci MJ et al. Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Groupe Francais de Cytogenetique Hematologique, Groupe Francais d'Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED I European Community-Concerted Action 'Molecular Cytogenetic Diagnosis in Haematological Malignancies'. Blood 2000; 96: 1297-1308.
30. Dong S, Zhu J, Reid A et al. Amino-terminal protein-protein interaction motif (POZ-domain) is responsible for activities of the promyelocytic leukemia zinc finger-retinoic acid receptor-alpha fusion protein. Proceedings of the National Academy of Sciences of the USA 1996; 93: 3624-3629.
31. Perez A, Kastner P, Sethi S et al. PMLRAR homodimers: distinct DNA binding properties and heteromeric interactions with RXR. EMBO Journal 1993; 12: 3171-3182.
32. Lin RJ & Evans RM. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Molecular Cell 2000; 5: 821-830.
33. Minucci S, Maccarana M, Cioce M et al. Oligomerization of RAR and AML 1 transcription factors as a novel mechanism of oncogenic activation. Molecular Cell 2000; 5: 811-820.
34. Pollock JL, Westervelt P, Kurichety AK et al. A bcr-3 isoform of RARalpha-PML potentiates the development of PML-RARalpha-driven acute promyelocytic leukemia. Proceedings of the National Academy of Sciences of the USA 1999; 96: 15103-15108.
35. He L, Bhaumik M, Tribioli C et al. Two critical hits for promyelocytic leukemia. Molecular Cell 2000; 6: 1131-1141.
36. Mozziconacci MJ, Liberatore C, Brunel V et al. In vitro response to all-trans retinoic acid of acute promyelocytic leukemias with nonreciprocal PML/RARA or RARA/PML fusion genes. Genes Chromosomes & Cancer 1998; 22: 241-250.
37. Rego EM & Pandolfi PP. Reciprocal products of chromosomal translocations in human cancer pathogenesis: key players or innocent bystanders? Trends in Molecular Medicine 2002; 8: 396-405.
38. Grimwade D, Gorman P, Duprez E et al. Characterization of cryptic rearrangements and variant translocations in acute promyelocytic leukemia. Blood 1997; 90: 4876-4885.
39. Zelent A, Guidez F, Melnick A et al. Translocations of the RARalpha gene in acute promyelocytic leukemia. Oncogene 2001; 20: 7186-7203.
40. Strudwick S & Borden KL. Finding a role for PML in APL pathogenesis: a critical assessment of potential PML activities. Leukemia 2002; 16: 1906-1917.
41. Salomoni P & Pandolfi PP. The role of PML in tumor suppression. Cell 2002; 108: 165-170.
42. Guo A, Salomoni P, Luo J et al. The function of PML in p53-dependent apoptosis. Nature Cell Biology 2000; 2: 730-736.
43. Bischof O, Kirsh O, Pearson M et al. Deconstructing PML-induced premature senescence. EMBO Journal 2002; 21: 3358-3369.
44. Ferbeyre G, de Stanchina E, Querido E et al. PML is induced by oncogenic ras and promotes premature senescence. Genes & Development 2000; 14: 2015-2027.
45. Pearson M, Carbone R, Sebastiani C et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 2000; 406: 207-210.
46. Blander G, Zalle N, Daniely Y et al. DNA damage-induced translocation of the Werner helicase is regulated by acetylation. Journal of Biological Chemistry 2002; 277: 50934-50940.
47. Wang XW, Tseng A, Ellis NA et al. Functional interaction of p53 and BLM DNA helicase in apoptosis. Journal of Biological Chemistry 2001; 276: 32948-32955.
48. Carbone R, Pearson M, Minucci S et al. PML NBs associate with the hMre11 complex and p53 at sites of irradiation induced DNA damage. Oncogene 2002; 21: 1633-1640.
49. Seker H, Rubbi C, Linke SP et al. UV-C-induced DNA damage leads to p53-dependent nuclear trafficking of PML. Oncogene 2003; 22: 1620-1628.
50. Wang ZG, Delva L, Gaboli M et al. Role of PML in cell growth and the retinoic acid pathway. Science 1998; 279: 1547-1551.
51. Topisirovic I, Culjkovic B, Cohen N et al. The proline-rich homeodomain protein, PRH, is a tissue-specific inhibitor of eIF4E-dependent cyclin D1 mRNA transport and growth. EMBO Journal 2003; 22: 689-703.
52. Cohen N, Sharma M, Kentsis A et al. PML RING suppresses oncogenic transformation by reducing the affinity of eIF4E for mRNA. EMBO Journal 2001; 20: 4547-4559.
53. Lai HK & Borden KL. The promyelocytic leukemia (PML) protein suppresses cyclin D1 protein production by altering the nuclear cytoplasmic distribution of cyclin D1 mRNA. Oncogene 2000; 19: 1623-1634.
54. Vallian S, Gaken JA, Trayner ID et al. Transcriptional repression by the promyelocytic leukemia protein, PML. Experimental Cell Research 1997; 237: 371-382.
55. Vallian S, Gaken JA, Gingold EB et al. Modulation of Fos-mediated AP-1 transcription by the promyelocytic leukemia protein. Oncogene 1998; 16: 2843-2853.
56. Khan MM, Nomura T, Kim H et al. Role of PML and PML-RARalpha in Mad-mediated transcriptional repression. Molecular Cell 2001; 7: 1233-1243.
57. Wu WS, Vallian S, Seto E et al. The growth suppressor PML represses transcription by functionally and physically interacting with histone deacetylases. Molecular & Cell Biology 2001; 21: 2259-2268.
58. Doucas V, Tini M, Egan DA et al. Modulation of CREB binding protein function by the promyelocytic (PML) oncoprotein suggests a role for nuclear bodies in hormone signaling. Proceedings of the National Academy of Sciences of the USA 1999; 96: 2627-2632.
59. LaMorte VJ, Dyck JA, Ochs RL et al. Localization of nascent RNA and CREB binding protein with the PML-containing nuclear body. Proceedings of the National Academy of Sciences of the USA 1998; 95: 4991-4996.
60. Slack JL, Arthur DC, Lawrence D et al. Secondary cytogenetic changes in acute promyelocytic leukemia - prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study. Journal of Clinical Oncology 1997; 15: 1786-1795
61. Vahdat L, Maslak P, Miller WJ et al. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 1994; 84: 3843-3849.
62. Fukutani H, Naoe T, Ohno R et al. Isoforms of PML-retinoic acid receptor alpha fused transcripts affect neither clinical features of acute promyelocytic leukemia nor prognosis after treatment with all-trans retinoic acid. The Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia 1995; 9: 1478-1482.
63. Grimwade D & Lo Coco F. Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia. Leukemia 2002; 16: 1959-1973.
64. Di Croce L, Raker VA, Corsaro M et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 2002; 295: 1079-1082.
65. Park DJ, Chumakov AM, Vuong PT et al. CCAAT/enhancer binding protein epsilon is a potential retinoid target gene in acute promyelocytic leukemia treatment. Journal of Clinical Investigation 1999; 103: 1399-1408. (see comments).
66. Truong BT, Lee YJ, Lodie TA et al. CCAAT/Enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemia. Blood 2003; 101: 1141-1148.
67. Borrow J, Goddard AD, Gibbons B et al. Diagnosis of acute promyelocytic leukaemia by RT-PCR: detection of PML-RARA and RARA-PML fusion transcripts. British Journal of Haematology 1992; 82: 529-540.
68. Alcalay M, Zangrilli D, Fagioli M et al. Expression pattern of the RAR alpha-PML fusion gene in acute promyelocytic leukemia. Proceedings of the National Academy of Sciences of the USA 1992; 89: 4840-4844.
69. Li YP, Andersen J, Zelent A et al. RAR alpha 1 /RAR alpha2-PML mRNA expression in acute promyelocytic leukemia cells: a molecular and laboratory-clinical correlative study. Blood 1997; 90: 306-312.
70. He LZ, Tribioli C, Rivi R et al. Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice. Proceedings of the National Academy of Sciences of the USA 1997; 94: 5302-5307.
71. Brown D, Kogan S, Lagasse E et al. A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proceedings of the National Academy of Sciences of the USA 1997; 94: 2551-2556.
72. Grisolano J, Wesselschmidt R, Pellici P et al. Altered myeloid development and acute leukemia in transgenic mice expressing PML-RARα under control of cathepsin G regulatory sequences. Blood 1997; 89: 376-387.
73. Wang Z-G, Rego E, Peruzzi D et al. Loss of PML function enhances the frequency and onset of APL in PML-RARα transgenic mice. Blood 1998; 92(supplement 1): 479a.
74. Noguera NI, Breccia M, Divona M et al. Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol. Leukemia 2002; 16: 2185-2189.
75. Kottaridis PD, Gale RE, Frew ME et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98: 1752-1759.
76. Kelly LM, Kutok JL, Williams IR et al. PML/RARalpha and FLT3-1TD induce an APL-like disease in a mouse model. Proceedings of the National Academy of Sciences of the USA 2002; 99: 8283-8288.
77. He LZ, Guidez F, Tribioli C et al. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nature Genetics 1998; 18: 126-135.
78. He LZ, Tolentino T, Grayson P et al. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. Journal of Clinical Investigation 2001; 108: 1321-1330.
79. Lallemand-Breitenbach V, Guillemin MC, Janin A et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. Journal of Experimental Medicine 1999; 189: 1043-1052.
80. Rego EM, He LZ, Warrell Jr. RP et al. Retinoic acid (RA) and As203 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proceedings of the National Academy of Sciences of the USA 2000; 97: 10173-10178.
81. Chen SJ, Zelent A, Tong JH et al. Rearrangements of the retinoic acid receptor alpha and promyelocytic leukemia zinc finger genes resulting from t(11;17)(q23;q21) in a patient with acute promyelocytic leukemia. Journal of Clinical Investigation 1993; 91: 2260-2267.
82. Licht JD, Chomienne C, Goy A et al. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood 1995; 85: 1083-1094.
83. Culligan DJ, Stevenson D, Chee YL et al. Acute promyelocytic leukaemia with t(11;17)(q23;q12-21) and a good initial response to prolonged ATRA and combination chemotherapy. British Journal of Haematology 1998; 100: 328-330.
84. Jansen JH, de Ridder MC, Geertsma WM et al. Complete remission of t(11;17) positive acute promyelocytic leukemia induced by all-trans retinoic acid and granulocyte colony-stimulating factor. Blood 1999; 94: 39-45.
85. Sainty D, Liso V, Cantu-Rajnoldi A et al. A new morphologic classification system for acute promyelocytic leukemia distinguishes cases with underlying PLZF/RARA gene rearrangements. Group Francais de Cytogenetique Hematologique, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Action 'Molecular Cytogenetic Diagnosis in Haematological Malignancies'. Blood 2000; 96: 1287-1296.
86. Petti MC, Fazi F, Gentile M et al. Complete remission through blast cell differentiation in PLZF/RARalpha-positive acute promyelocytic leukemia: in vitro and in vivo studies. Blood 2002; 100: 1065-1067.
87. Li JY, English MA, Ball HJ et al. Sequence-specific DNA binding and transcriptional regulation by the promyelocytic leukemia zinc finger protein. Journal of Biological Chemistry 1997; 272: 22447-22455.
88. Sitterlin D, Tiollais P & Transy C. The RAR alpha-PLZF chimera associated with acute promyelocytic leukemia has retained a sequence-specific DNA-binding domain. Oncogene 1997; 14: 1067-1074.
89. Ball HJ, Melnick A, Shaknovich R et al. The promyelocytic leukemia zinc finger (PLZF) protein binds DNA in a high molecular weight complex associated with cdc2 kinase. Nucleic Acids Research 1999; 27: 4106-4113.
90. Bardwell VJ & Treisman R. The POZ domain: a conserved protein-protein interaction motif. Genes & Development 1994; 8: 1664-1677.
91. Numoto M, Niwa O, Kaplan J et al. Transcriptional repressor ZF5 identifies a new conserved domain in zinc finger proteins. Nucleic Acids Research 1993; 21: 3767-3775.
92. Chang CC, Ye BH, Chaganti RS et al. BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor. Proceedings of the National Academy of Sciences of the USA 1996; 93: 6947-6952.
93. Reid A, Gould A, Brand N et al. Leukemia translocation gene, PLZF, is expressed with a speckled nuclear pattern in early hematopoietic progenitors. Blood 1995; 86: 4544-4552.
94. Licht JD, Shaknovich R, English MA et al. Reduced and altered DNA-binding and transcriptional properties of the PLZF-retinoic acid receptor-alpha chimera generated in t(11;17)-associated acute promyelocytic leukemia. Oncogene 1996; 12: 323-336.
95. Koken MH, Reid A, Quignon F et al. Leukemia-associated retinoic acid receptor alpha fusion partners, PML and PLZF, heterodimerize and colocalize to nuclear bodies. Proceedings of the National Academy of Sciences of the USA 1997; 94: 10255-10260.
96. Ruthardt M, Orleth A, Tomassoni L et al. The acute promyelocytic leukemia specific PML and PLZF proteins localize to adjacent and functionally distinct nuclear bodies. Oncogene 1998; 16: 1945-1953.
97. Hummel JL, Wells RA, Dube ID et al. Deregulation of NPM and PLZF in a variant t(5;17) case of acute promyelocytic leukemia. Oncogene 1999; 18: 633-641.
98. Ward JO, McConnell MJ, Carlile GW et al. The acute promyelocytic leukemia-associated protein, promyelocytic leukemia zinc finger, regulates 1,25-dihydroxyvitamin D(3)-induced monocytic differentiation of U937 cells through a physical interaction with vitamin D(3) receptor. Blood 2001; 98: 3290-3300.
99. Labbaye C, Quaranta MT, Pagliuca A et al. PLZF induces megakaryocytic development, activates Tpo receptor expression and interacts with GATA1 protein. Oncogene 2002; 21: 6669-6679.
100. Cook M, Gould A, Brand N et al. Expression of the zinc-finger gene PLZF at rhombomere boundaries in the vertebrate hindbrain. Proceedings of the National Academy of Sciences of the USA 1995; 92: 2249-2253.
101. Barna M, Hawe N, Niswander L et al. Plzf regulates limb and axial skeletal patterning. Nature Genetics 2000; 25: 166-172.
102. Barna M, Merghoub T, Costoya JA et al. Plzf mediates transcriptional repression of HoxD gene expression through chromatin remodeling. Developmental Cell 2002; 3: 499-510.
103. Look AT. Oncogenic transcription factors in the human acute leukemias. Science 1997; 278: 1059-1064.
104. Yu BD, Hess JL, Horning SE et al. Altered Hox expression and segmental identity in M11-mutant mice. Nature 1995; 378: 505-508.
105. Shaknovich R, Yeyati PL, Ivins S et al. The promyelocytic leukemia zinc finger protein affects myeloid cell growth, differentiation, and apoptosis. Molecular & Cell Biology 1998; 18: 5533-5545.
106. Yeyati PL, Shaknovich R, Boterashvili S et al. Leukemia translocation protein PLZF inhibits cell growth and expression of cyclin A. Oncogene 1999; 18: 925-934.
107. McConnell M, Chevallier N, Giltnane J et al. C-myc is a target for regulation by PLZF: two alternative mechanisms for down-regulation of gene expression. Blood 2000; 96(supplement 1): 457a.
108. Ruthardt M, Testa U, Nervi C et al. Opposite effects of the acute promyelocytic leukemia PML-retinoic acid receptor alpha (RAR alpha) and PLZF-RAR alpha fusion proteins on retinoic acid signalling. Molecular & Cell Biology 1997; 17: 4859-4869.
109. David G, Alland L, Hong SH et al. Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein. Oncogene 1998; 16: 2549-2556.
110. Grignani F, De Matteis S, Nervi C et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukemia. Nature 1998; 391: 815-818.
111. Guidez F, Ivins S, Zhu J et al. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood 1998; 91: 2634-2642.
112. Hong SH, David G, Wong CW et al. SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor alpha (RARalpha) and PLZF-RARalpha oncoproteins associated with acute promyelocytic leukemia. Proceedings of the National Academy of Sciences of the USA 1997; 94: 9028-9033.
113. Lin RJ, Nagy L, Inoue S et al. Role of the histone deacetylase complex in acute promyelocytic leukemia. Nature 1998; 391: 811-814.
114. Wong CW & Privalsky ML. Components of the SMRT corepressor complex exhibit distinctive interactions with the POZ domain oncoproteins PLZF, PLZF-RARalpha, and BCL-6. Journal of Biological Chemistry 1998; 273: 27695-27702.
115. Downes M, Ordentlich P, Kao HY et al. Identification of a nuclear domain with deacetylase activity. Proceedings of the National Academy of Sciences of the USA 2000; 97: 10330-10335.
116. Melnick AM, Westendorf JJ, Polinger A et al. The ETO protein disrupted in t(8;21)-associated acute myeloid leukemia is a corepressor for the promyelocytic leukemia zinc finger protein. Molecular & Cell Biology 2000; 20: 2075-2086.
117. Melnick A, Ahmad KF, Arai S et al. In-depth mutational analysis of the promyelocytic leukemia zinc finger BTB/POZ domain reveals motifs and residues required for biological and transcriptional functions. Molecular & Cell Biology 2000; 20: 6550-6567.
118. Melnick A, Carlile G, Ahmad KF et al. Critical residues within the BTB domain of PLZF and Bcl-6 modulate interaction with corepressors. Molecular & Cell Biology 2002; 22: 1804-1818.
119. Nagpal S, Saunders M, Kastner P et al. Promoter context- and response element-dependent specificity of the transcriptional activation and modulating functions of retinoic acid receptors. Cell 1992; 70: 1007-1019.
120. Hauksdottir H & Privalsky ML. DNA recognition by the aberrant retinoic acid receptors implicated in human acute promyelocytic leukemia. Cell Growth & Differentiation 2001; 12: 85-98.
121. So CW, Dong S, So CK et al. The impact of differential binding of wild-type RARalpha, PML-, PLZF- and NPM-RARalpha fusion proteins towards transcriptional co-activator, RIP-140, on retinoic acid responses in acute promyelocytic leukemia. Leukemia 2000; 14: 77-83.
122. Chen Z, Guidez F, Rousselot P et al. PLZF-RAR alpha fusion proteins generated from the variant t(11; 17)(q23;q21) translocation in acute promyelocytic leukemia inhibit ligand-dependent transactivation of wild-type retinoic acid receptors. Proceedings of the National Academy of Sciences of the USA 1994; 91: 1178-1182.
123. Puccetti E, Obradovic D, Beissert T et al. AML-associated translocation products block vitamin D(3)-induced differentiation by sequestering the vitamin D(3) receptor. Cancer Research 2002; 62: 7050-7058.
124. Melnick A, Carlile GW, McConnell MJ et al. AML-1/ETO fusion protein is a dominant negative inhibitor of transcriptional repression by the promyelocytic leukemia zinc finger protein. Blood 2000; 96: 3939-3947.
125. Koken MH, Daniel MT, Gianni M et al. Retinoic acid, but not arsenic trioxide, degrades the PLZF/ RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient. Oncogene 1999; 18: 1113-1118.
126. Cheng GX, Zhu XH, Men XQ et al. Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARalpha and NPM-RARalpha. Proceedings of the National Academy of Sciences of the USA 1999; 96: 6318-6323.
127. Guidez F, Huang W, Tong JH et al. Poor response to all-trans retinoic acid therapy in a t(11;17) PLZF/ RAR alpha patient. Leukemia 1994; 8: 312-317.
128. Morris S, Kirstein M, Valentine M et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in a non-Hodgkin's lymphoma. Science 1994; 263: 1281-1284.
129. ALK: a distinct clinicopathologic entity. Blood 1995; 86: 1954-1960.
130. Iwahara T, Fujimoto J, Wen D et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 1997; 14: 439-449.
131. Yoneda-Kato N, Look T, Kirstein M et al. The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1. Oncogene 1996; 10: 265-275.
132. Olson O, Orrick L, Jones C et al. Phosphorylation of acid soluble nucleolar proteins of Novikoff hepatoma ascites cells in vivo. Journal of Biological Chemistry 1974; 249: 2823-2827.
133. Hernandez-Verdun D, Derenzeni M & Bouteille M. The morphological relationship in electron microscopy between NOR-silver proteins and intranuclear chromatin. Chromosoma 1982; 85: 461-473.
134. Chan P & Chan F. Nucleophosmin/B23 (NPM) oligomer is a major and stable entity in HeLa cells. Biochimica et Biophysica Acta 1995; 1262: 37-42.
135. Smetana K, Ochs R, Lischwe M et al. Immunofluorescence studies on proteins B23 and C23 in nucleoli of human lymphocytes. Experimental Cell Research 1984; 152: 195-203.
136. Dumbar T, Gentry G & Olson M. Interaction of nucleolar phosphoprotein with nucleic acids. Biochemistry 1989; 28: 9495-9501.
137. Borer RA, Lehner CF, Eppenberger HM et al. Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell 1989; 56: 379-390.
138. Szebeni A, Mehrotra B, Baumann A et al. Nucleolar protein B23 stimulates nuclear import of the HIV-1 Rev protein and NLS-conjugated albumin. Biochemistry 1997; 36: 3941-3949.
139. Okuda M, Horn HF, Tarapore P et al. Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell 2000; 103: 127-140.
140. Okuda M. The role of nucleophosmin in centrosome duplication. Oncogene 2002; 21: 6170-6174.
141. Tawfic S, Olson M & Ahmed K. Role of protein phosphorylation in post-translational regulation of protein B23 during programmed cell death in the prostate gland. Journal of Biological Chemistry 1995; 270: 21009-21015.
142. Chan PK & Chan FY. A study of correlation between NPM-translocation and apoptosis in cells induced by daunomycin. Biochemical Pharmacology 1999; 57: 1265-1273.
143. Yung B, Busch R, Busch H et al. Effects of actinomycin D analogs on nucleolar phosphoprotein B23 (39 kDa/p15.1). Biochemical Pharmacology 1985; 34: 4059-4063.
144. Yung B, Busch H & Chan P. Translocation of nucleolar phosphoprotein B23 (37 kDa/P15.1) induced by inhibitors of ribosome synthesis. Biochimica et Biophysica Acta 1985; 826: 167-173.
145. Colombo E, Marine JC, Danovi D et al. Nucleophosmin regulates the stability and transcriptional activity of p53. Nature Cell Biology 2002; 4: 529-533.
146. Serrano M, Lin AW, McCurrach ME et al. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p161NK4a. Cell 1997; 88: 593-602.
147. Redner RL, Corey SJ & Rush EA. Differentiation of t(5;17) variant acute promyelocytic leukemic blasts by all-trans retinoic acid. Leukemia 1997; 11: 1014-1016.
148. Redner RL, Chen JD, Rush EA et al. The t(5;17) acute promyelocytic leukemia fusion protein NPM-RAR interacts with co-repressor and co-activator proteins and exhibits both positive and negative transcriptional properties. Blood 2000; 95: 2683-2690.
149. Redner R, Rush L & Pollock S. Forced expression of the NPM/RAR fusion gene inhibits differentiation of U937 cells. Blood 1996; 10: 551a.
150. Compton DA, Szilak I & Cleveland DW. Primary structure of NuMA, an intranuclear protein that defines a novel pathway for segregation of proteins at mitosis. Journal of Cell Biology 1992; 116: 1395-1408.
151. Compton DA & Cleveland DW. NuMA, a nuclear protein involved in mitosis and nuclear reformation. Current Opinion in Cell Biology 1994; 6: 343-346.
152. He D, Zeng C & Brinkley BR. Nuclear matrix proteins as structural and functional components of the mitotic apparatus. International Review of Cytology 1995; 162B: 1-74.
153. Saredi A, Howard L & Compton DA. NuMA assembles into an extensive filamentous structure when expressed in the cell cytoplasm. Journal of Cell Science 1996; 109: 619-630.
154. Sparks CA, Bangs PL, McNeil GP et al. Assignment of the nuclear mitotic apparatus protein NuMA gene to human chromosome 11q13. Genomics 1993; 17: 222-224.
155. Harborth J, Weber K & Osborn M. Epitope mapping and direct visualization of the parallel, in-register arrangement of the double-stranded coiled-coil in the NuMA protein. EMBO Journal 1995; 14: 2447-2460.
156. Zeng C. NuMA: a nuclear protein involved in mitotic centrosome function. Microscopy Research & Technique 2000; 49: 467-477.
157. Wells R & Kamel-Reid S. NuMA-RARA, a new gene fusion in promyelocytic leukemia. Blood 1996; 88(supplement 1): 365a.
158. Compton DA & Cleveland DW. NuMA is required for the proper completion of mitosis. Journal of Cell Biology 1993; 120: 947-957.
159. Maekawa T & Kuriyama R. Primary structure and microtubule-interacting domain of the SP-H antigen: a mitotic MAP located at the spindle pole and characterized as a homologous protein to NuMA. Journal of Cell Science 1993; 105: 589-600.
160. Dong S, Qiu J, Stenoien DL et al. Essential role for the dimerization domain of NuMA-RARalpha in its oncogenic activities and localization to NuMA sites within the nucleus. Oncogene 2003; 22: 858-868.
161. Levy DE & Darnell Jr. JE. Stats: transcriptional control and biological impact. Nature Reviews Molecular Cell Biology 2002; 3: 651-662.
162. Chretien S, Varlet P, Verdier F et al. Erythropoietin-induced erythroid differentiation of the human erythroleukemia cell line TF-1 correlates with impaired STAT5 activation. EMBO Journal 1996; 15: 4174-4181.
163. Dong F, Liu X, de Koning JP et al. Stimulation of Stat5 by granulocyte colony-stimulating factor (G-CSF) is modulated by two distinct cytoplasmic regions of the G-CSF receptor. Journal of Immunology 1998; 161: 6503-6509.
164. Mui AL, Wakao H, Kinoshita T et al. Suppression of interleukin-3-induced gene expression by a C-terminal truncated Stat5: role of Stat5 in proliferation. EMBO Journal 1996; 15: 2425-2433.
165. Lin JX & Leonard WJ. The role of Stat5a and Stat5b in signaling by IL-2 family cytokines. Oncogene 2000; 19: 2566-2576.
166. Teglund S, McKay C, Schuetz E et al. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine
167. Imada K, Bloom ET, Nakajima H et al. Stat5b is essential for natural killer cell-mediated proliferation and cytolytic activity. Journal of Experimental Medicine 1998; 188: 2067-2074.
168. Matikainen S, Sareneva T, Ronni T et al. Interferon-alpha activates multiple STAT proteins and upregulates proliferation-associated IL-2Ralpha, c-myc, and pim-1 genes in human T cells. Blood 1999; 93: 1980-1991.
169. Nieborowska-Skorska M, Wasik MA, Slupianek A et al. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ ABL and is required for leukemogenesis. Journal of Experimental Medicine 1999; 189: 1229-1242.
170. Kieslinger M, Woldman I, Moriggl R et al. Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation. Genes & Development 2000; 14: 232-244.
171. Santos SC, Lacronique V, Bouchaert I et al. Constitutively active STAT5 variants induce growth and survival of hematopoietic cells through a Pl 3-kinase/Akt dependent pathway. Oncogene 2001; 20: 2080-2090.
172. Kazansky AV & Rosen JM. Signal transducers and activators of transcription 5B potentiates v-Src-mediated transformation of NIH-3T3 cells. Cell Growth & Differentiation 2001; 12: 1-7.
173. Zhu M, John S, Berg M et al. Functional association of Nmi with Stat5 and Stat1 in 1L-2-and 1FNgamma-mediated signaling. Cell 1999; 96: 121-130.
174. Dong S & Tweardy DJ. Interactions of STAT5b-RARalpha, a novel acute promyelocytic leukemia fusion protein, with retinoic acid receptor and STAT3 signaling pathways. Blood 2002; 99: 2637-2646.
175. Nakamaki T. Hino K, Yokoyama A et al. Effect of cytokines on the proliferation and differentiation of acute promyelocytic leukemia cells: possible relationship to the development of retinoic acid syndrome. Anticancer Research 1994; 14: 817-823.
176. Pandolfi PP et al. Genomic variability and alternative splicing generate multiple PML/RARα transcripts that encode aberrant PML proteins and PML-RARα isoforms in accute promyelocytic leukaemia. EMBO Journal 1992; 11(4): 1397-1407.